Jeff Alder

4.0k total citations
37 papers, 3.0k citations indexed

About

Jeff Alder is a scholar working on Infectious Diseases, Clinical Biochemistry and Epidemiology. According to data from OpenAlex, Jeff Alder has authored 37 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 13 papers in Clinical Biochemistry and 12 papers in Epidemiology. Recurrent topics in Jeff Alder's work include Antimicrobial Resistance in Staphylococcus (18 papers), Bacterial Identification and Susceptibility Testing (13 papers) and Pneumonia and Respiratory Infections (7 papers). Jeff Alder is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (18 papers), Bacterial Identification and Susceptibility Testing (13 papers) and Pneumonia and Respiratory Infections (7 papers). Jeff Alder collaborates with scholars based in United States, Germany and United Kingdom. Jeff Alder's co-authors include Jared Silverman, Grace M. Thorne, Lisa Friedman, Judith N. Steenbergen, Francis P. Tally, Lawrence I. Mortin, Tongchuan Li, George Sakoulas, George M. Eliopoulos and Carmela Mascio and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Clinical Microbiology and Journal of Medicinal Chemistry.

In The Last Decade

Jeff Alder

37 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeff Alder United States	24	1.5k	838	816	771	521	37	3.0k
Sandra Tallent United States	16	2.7k 1.7×	973 1.2×	920 1.1×	1.8k 2.3×	332 0.6×	42	4.5k
Peter K. Linden United States	25	1.4k 0.9×	462 0.6×	932 1.1×	869 1.1×	414 0.8×	34	2.8k
Mondell L. Beach United States	21	1.3k 0.8×	652 0.8×	996 1.2×	750 1.0×	549 1.1×	31	2.8k
Martín E. Stryjewski United States	35	2.9k 1.9×	996 1.2×	1.4k 1.8×	1.5k 1.9×	668 1.3×	80	4.6k
Dwight J. Hardy United States	27	825 0.5×	612 0.7×	327 0.4×	1.2k 1.6×	674 1.3×	89	3.0k
James S. Lewis United States	40	1.9k 1.2×	522 0.6×	673 0.8×	1.8k 2.4×	774 1.5×	99	4.6k
Beth P. Goldstein United States	30	2.2k 1.4×	1.0k 1.2×	528 0.6×	1.2k 1.5×	939 1.8×	74	3.7k
Andrea Novelli Italy	34	950 0.6×	471 0.6×	421 0.5×	1.2k 1.6×	1.3k 2.6×	166	3.7k
Kristopher P. Heilmann United States	25	874 0.6×	501 0.6×	318 0.4×	1.4k 1.8×	418 0.8×	32	2.7k
Robert H.K. Eng United States	33	1.5k 1.0×	510 0.6×	467 0.6×	1.5k 1.9×	598 1.1×	116	3.4k

Countries citing papers authored by Jeff Alder

Since Specialization

Citations

This map shows the geographic impact of Jeff Alder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Alder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Alder more than expected).

Fields of papers citing papers by Jeff Alder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Alder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Alder. The network helps show where Jeff Alder may publish in the future.

Co-authorship network of co-authors of Jeff Alder

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Alder. A scholar is included among the top collaborators of Jeff Alder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Alder. Jeff Alder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lv, Xiaoju, Jeff Alder, Li Li, et al.. (2019). Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection. Antimicrobial Agents and Chemotherapy. 63(7). 25 indexed citations

Niederman, Michael S., Jeff Alder, Matteo Bassetti, et al.. (2019). Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. The Lancet Infectious Diseases. 20(3). 330–340. 87 indexed citations

Karlowsky, James A., Meredith Hackel, Samuel K. Bouchillon, Jeff Alder, & Daniel F. Sahm. (2017). In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016. Diagnostic Microbiology and Infectious Disease. 89(2). 151–157. 15 indexed citations

Biedenbach, Douglas J., et al.. (2016). In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China. European Journal of Clinical Microbiology & Infectious Diseases. 35(12). 1933–1939. 8 indexed citations

Rex, John, Barry I. Eisenstein, Jeff Alder, et al.. (2013). A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. The Lancet Infectious Diseases. 13(3). 269–275. 92 indexed citations

Waele, Jan J. De, José M. Tellado, Jeff Alder, et al.. (2012). Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study. International Journal of Antimicrobial Agents. 41(1). 57–64. 17 indexed citations

Wilson, Robert, Tobias Welte, Eva Polverino, et al.. (2012). Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal. 41(5). 1107–1115. 160 indexed citations

Schaper, Nicolaas C., Matthew Dryden, P. Kujath, et al.. (2012). Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection. 41(1). 175–186. 43 indexed citations

Gyssens, Inge C., Matthew Dryden, P. Kujath, et al.. (2011). A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy. 66(11). 2632–2642. 48 indexed citations

10.

Wilson, Robert, Antonio Anzueto, Marc Miravitlles, et al.. (2011). Moxifloxacinversusamoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. European Respiratory Journal. 40(1). 17–27. 58 indexed citations

11.

Wilson, Robert C., Tobias Welte, Eva Polverino, et al.. (2011). Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. European Respiratory Journal. 38(Suppl 55). 1929–1929. 5 indexed citations

12.

Alder, Jeff, Robert C. Wilson, Tobias Welte, et al.. (2011). Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. European Respiratory Journal. 38(Suppl 55). 1930–1930. 4 indexed citations

13.

Pertel, Peter, Patricia Bernardo, Charles Fogarty, et al.. (2008). Effects of Prior Effective Therapy on the Efficacy of Daptomycin and Ceftriaxone for the Treatment of Community‐Acquired Pneumonia. Clinical Infectious Diseases. 46(8). 1142–1151. 106 indexed citations

14.

Morgan, Margie, et al.. (2008). In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-resistant isolates. Diagnostic Microbiology and Infectious Disease. 61(3). 339–342. 6 indexed citations

15.

Thorne, Grace M., et al.. (2006). In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. International Journal of Antimicrobial Agents. 28(5). 385–388. 28 indexed citations

16.

Steenbergen, Judith N., Jeff Alder, Grace M. Thorne, & Francis P. Tally. (2005). Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. Journal of Antimicrobial Chemotherapy. 55(3). 283–288. 422 indexed citations

17.

Silverman, Jared, et al.. (2005). Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact. The Journal of Infectious Diseases. 191(12). 2149–2152. 398 indexed citations

18.

Bitzer, Johannes, et al.. (2004). Acceptability and side-effects of Implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group. The European Journal of Contraception & Reproductive Health Care. 9(4). 278–284. 43 indexed citations

19.

Thorne, Grace M. & Jeff Alder. (2002). Daptomycin: a novel lipopeptide antibiotic. Clinical Microbiology Newsletter. 24(5). 33–40. 51 indexed citations

20.

Li, Qun, Weibo Wang, Akiyo Claiborne, et al.. (1998). Synthesis and structure-activity relationships of 2-pyridones: II. 8-(Fluoro-substituted pyrrolidinyl)-2-pyridones as antibacterial agents. Bioorganic & Medicinal Chemistry Letters. 8(15). 1953–1958. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact